Logo image of XNCR

XENCOR INC (XNCR) Stock Fundamental Analysis

NASDAQ:XNCR - US98401F1057 - Common Stock

8.13 USD
+0.08 (+0.99%)
Last: 8/29/2025, 8:00:22 PM
8.13 USD
0 (0%)
After Hours: 8/29/2025, 8:00:22 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XNCR. XNCR was compared to 547 industry peers in the Biotechnology industry. XNCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XNCR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XNCR has reported negative net income.
In the past year XNCR has reported a negative cash flow from operations.
XNCR had negative earnings in 4 of the past 5 years.
In the past 5 years XNCR reported 4 times negative operating cash flow.
XNCR Yearly Net Income VS EBIT VS OCF VS FCFXNCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

XNCR has a Return On Assets of -20.23%. This is in the better half of the industry: XNCR outperforms 76.78% of its industry peers.
With a decent Return On Equity value of -28.67%, XNCR is doing good in the industry, outperforming 78.25% of the companies in the same industry.
Industry RankSector Rank
ROA -20.23%
ROE -28.67%
ROIC N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
XNCR Yearly ROA, ROE, ROICXNCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XNCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XNCR Yearly Profit, Operating, Gross MarginsXNCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XNCR has been increased compared to 1 year ago.
The number of shares outstanding for XNCR has been increased compared to 5 years ago.
Compared to 1 year ago, XNCR has an improved debt to assets ratio.
XNCR Yearly Shares OutstandingXNCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XNCR Yearly Total Debt VS Total AssetsXNCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.33, we must say that XNCR is in the distress zone and has some risk of bankruptcy.
XNCR's Altman-Z score of 0.33 is fine compared to the rest of the industry. XNCR outperforms 61.61% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that XNCR is not too dependend on debt financing.
XNCR's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. XNCR is outperformed by 65.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 0.33
ROIC/WACCN/A
WACC9.36%
XNCR Yearly LT Debt VS Equity VS FCFXNCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

XNCR has a Current Ratio of 5.34. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR's Current ratio of 5.34 is in line compared to the rest of the industry. XNCR outperforms 57.77% of its industry peers.
XNCR has a Quick Ratio of 5.34. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR has a Quick ratio of 5.34. This is comparable to the rest of the industry: XNCR outperforms 58.87% of its industry peers.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 5.34
XNCR Yearly Current Assets VS Current LiabilitesXNCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.96% over the past year.
The Revenue has grown by 17.52% in the past year. This is quite good.
The Revenue has been decreasing by -6.75% on average over the past years.
EPS 1Y (TTM)16.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.68%
Revenue 1Y (TTM)17.52%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%157.12%

3.2 Future

XNCR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.95% yearly.
Based on estimates for the next years, XNCR will show a very strong growth in Revenue. The Revenue will grow by 51.15% on average per year.
EPS Next Y23.89%
EPS Next 2Y8.76%
EPS Next 3Y8.08%
EPS Next 5Y15.95%
Revenue Next Year119.14%
Revenue Next 2Y46.56%
Revenue Next 3Y35.41%
Revenue Next 5Y51.15%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XNCR Yearly Revenue VS EstimatesXNCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
XNCR Yearly EPS VS EstimatesXNCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XNCR. In the last year negative earnings were reported.
Also next year XNCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XNCR Price Earnings VS Forward Price EarningsXNCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XNCR Per share dataXNCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.76%
EPS Next 3Y8.08%

More info and screens

0

5. Dividend

5.1 Amount

XNCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENCOR INC

NASDAQ:XNCR (8/29/2025, 8:00:22 PM)

After market: 8.13 0 (0%)

8.13

+0.08 (+0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners113.14%
Inst Owner Change4.18%
Ins Owners1.1%
Ins Owner Change2.13%
Market Cap579.83M
Analysts84.44
Price Target26.29 (223.37%)
Short Float %13.17%
Short Ratio13.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.33%
Min EPS beat(2)-7.54%
Max EPS beat(2)44.19%
EPS beat(4)3
Avg EPS beat(4)22.04%
Min EPS beat(4)-7.54%
Max EPS beat(4)44.19%
EPS beat(8)4
Avg EPS beat(8)-20.8%
EPS beat(12)7
Avg EPS beat(12)-5.59%
EPS beat(16)9
Avg EPS beat(16)85.12%
Revenue beat(2)2
Avg Revenue beat(2)77.62%
Min Revenue beat(2)55.9%
Max Revenue beat(2)99.34%
Revenue beat(4)3
Avg Revenue beat(4)75%
Min Revenue beat(4)-20.99%
Max Revenue beat(4)165.74%
Revenue beat(8)5
Avg Revenue beat(8)39.73%
Revenue beat(12)8
Avg Revenue beat(12)32.26%
Revenue beat(16)11
Avg Revenue beat(16)43.61%
PT rev (1m)-11.45%
PT rev (3m)-17.14%
EPS NQ rev (1m)7.37%
EPS NQ rev (3m)19.58%
EPS NY rev (1m)13.8%
EPS NY rev (3m)11.63%
Revenue NQ rev (1m)20.28%
Revenue NQ rev (3m)58.89%
Revenue NY rev (1m)24.49%
Revenue NY rev (3m)22.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.69
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-2.4
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-1.97
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS2.2
BVpS8.7
TBVpS8.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.23%
ROE -28.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.21%
Cap/Sales 4.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 5.34
Altman-Z 0.33
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)252.19%
Cap/Depr(5y)241.55%
Cap/Sales(3y)15.72%
Cap/Sales(5y)12.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.68%
EPS Next Y23.89%
EPS Next 2Y8.76%
EPS Next 3Y8.08%
EPS Next 5Y15.95%
Revenue 1Y (TTM)17.52%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%157.12%
Revenue Next Year119.14%
Revenue Next 2Y46.56%
Revenue Next 3Y35.41%
Revenue Next 5Y51.15%
EBIT growth 1Y22.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.15%
EBIT Next 3Y11.28%
EBIT Next 5Y9.12%
FCF growth 1Y-3.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.14%
OCF growth 3YN/A
OCF growth 5YN/A